Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 05 2020 - 7:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16
of the Securities Exchange Act of 1934
Date of Report: November 5, 2020
Commission File Number: 001-39307
Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)
2101
Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Legend Biotech Announcement Regarding ASH 2020 Data Presentation for
Cilta-cel
On November 5, 2020, Legend Biotech Corporation (Legend Biotech) issued a press
release announcing that new and updated data from CARTITUDE-1 and LEGEND-2 studies, respectively, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually between December 5th and 8th, 2020. The press release is attached to this Form 6-K as Exhibit 99.1.
Cautionary Note Regarding Forward-Looking Statements
Statements in this Form 6-K about future expectations, plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend
Biotechs clinical efforts, its partnership with Janssen, and the data relating to CARTITUDE-1 and LEGEND-2 studies. The words anticipate,
believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should,
target, will, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially
from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the Risk Factors section of the Companys prospectus filed with the Securities and Exchange
Commission on June 8, 2020. Any forward-looking statements contained in this Form 6-K speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
LEGEND BIOTECH CORPORATION
(Registrant)
|
|
|
|
|
November 5, 2020
|
|
|
|
By:
|
|
/s/ Ying Huang
|
|
|
|
|
|
|
Ying Huang, Ph.D.
|
|
|
|
|
|
|
Chief Financial Officer and Interim Chief Executive Officer
|
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jul 2023 to Jul 2024